Skip to main content
SpringerLink
Log in

Estramustine phosphate: role in treating men with prostate cancer remains to be defined

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Perry CM, McTavish D. Estramustine phosphate sodium: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drug Aging 1995 Jul; 7(1): 49–74

    Article  CAS  Google Scholar 

  2. British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 334

  3. 1995 Physicians GenRx. St. Louis, Missouri: Mosby-Year Book, Inc. 1995; 754–5

  4. Denis LJ. Controversies in the management of localised and metastatic prostatic cancer. Eur J Cancer 1991; 27(3): 333–41

    Article  PubMed  CAS  Google Scholar 

  5. Cyproterone in the treatment of men with advanced prostate cancer. Drug Ther Perspect 1994 Nov 11; 4(10): 1–4

  6. Johansson JE, Andersson SO, Beckman KW, et al. Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate. Am J Clin Oncol 1988;11 Suppl. 2: S183–6

    Article  PubMed  Google Scholar 

  7. Kühn MW, Weiβbach L, Hinke A. Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. Urology 1994 Feb; 43(2 Suppl.): 61–7

    Article  PubMed  Google Scholar 

  8. Newling DWW, Fossa SD, Tunn UW, et al. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, Genitourinary Group prospective randomized phase III study (30965). J Urol 1993 Dec; 150: 1840–44

    PubMed  CAS  Google Scholar 

  9. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098–109

    Article  PubMed  CAS  Google Scholar 

  10. Murphy GP, Slack NH, Mittelman A. Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by Roswell Park Memorial Institute. Urology 1984 Jun; 23 Suppl.: 54–63

    Article  PubMed  CAS  Google Scholar 

  11. Benson R, Hartley-Asp B. Mechanisms of action and clinical uses of estramustine. Can Invest 1990; 8(3/4): 375–80

    Article  CAS  Google Scholar 

  12. Iversen P, Rasmussen F. Estramustine phosphate versus placebo in hormone refractory prostate cancer. Danish Prostatic Cancer Group Study 9002 [abstract]. J Urol 1995 Apr; 153 Suppl 239

    Google Scholar 

  13. Tveter KJ, Hagen S, Holme I, et al. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study. Scand J Urol Nephrol 1990; 24(4): 243–7

    PubMed  CAS  Google Scholar 

  14. Roessler W, Hinke A, Weiland WF. Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate. Urology 1994 Feb; 43 Suppl.: 57–60

    Article  PubMed  CAS  Google Scholar 

  15. Flamm J, Fischer M. Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade + cytostasis (orchiectomy + estramustine) in the management of previously untreated advanced prostatic cancer [in German]. Wein Klin Wochenschr 1988 Sep 9; 100: 589–92

    CAS  Google Scholar 

  16. Lundgren R, Nordle Ö, Josefsson K, et al. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. J Urol 1995 May; 153: 1580–6

    Article  PubMed  CAS  Google Scholar 

  17. Schmidt JD, Gibbons RP, Murphy GP, et al. Adjuvant therapy for localized prostate cancer. Cancer 1993 Feb; 71 Suppl.: 1005–13

    Article  PubMed  CAS  Google Scholar 

  18. Slack NH, Murphy GP. Clinical toxicity and long-term results of Emcyt therapy for prostate cancer. Urology 1984 Jun; 23 Suppl.: 73–7

    Article  PubMed  CAS  Google Scholar 

  19. Smith PH, Suciu S, Robinson MRG, et al. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol 1986 Sep; 136: 619–23

    PubMed  CAS  Google Scholar 

  20. Benson RC, Gill GM. Estramustine phosphate compared with diethylstilbestrol: a randomized, double-blind, crossover trial for stage D prostate cancer. Am J Clin Oncol 1986; 9(4): 341–51

    Article  PubMed  Google Scholar 

  21. de Voogt HJ, Smith PH, Pavone-Macaluso, et al. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986 Feb; 135: 303–7

    PubMed  Google Scholar 

  22. Lundgren R, Sundin T, Colleen S, et al. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. Scand J Urol Nephrol 1986; 20: 101–5

    Article  PubMed  CAS  Google Scholar 

  23. Hedlund PO, Gustaf son H, SjÖgren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. Scand J Urol Nephrol 1980; Suppl. 55: 103–5

    CAS  Google Scholar 

  24. de Kernion JN, Murphy GP, Priore R. Comparison of flutamide and emcyt in hormone-refractory metastatic prostatic cancer. Urology 1988 Apr; 31(4): 312–7

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Estramustine phosphate: role in treating men with prostate cancer remains to be defined. Drugs Ther. Perspect 6, 5–8 (1995). https://doi.org/10.2165/00042310-199506110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199506110-00002

Search

Navigation